Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

437 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Optimizing the Use of Gene Expression Profiling in Early-Stage Breast Cancer.
Kim HS, Umbricht CB, Illei PB, Cimino-Mathews A, Cho S, Chowdhury N, Figueroa-Magalhaes MC, Pesce C, Jeter SC, Mylander C, Rosman M, Tafra L, Turner BM, Hicks DG, Jensen TA, Miller DV, Armstrong DK, Connolly RM, Fetting JH, Miller RS, Park BH, Stearns V, Visvanathan K, Wolff AC, Cope L. Kim HS, et al. Among authors: visvanathan k. J Clin Oncol. 2016 Dec 20;34(36):4390-4397. doi: 10.1200/JCO.2016.67.7195. Epub 2016 Oct 31. J Clin Oncol. 2016. PMID: 27998227 Free PMC article.
A phase I vaccine safety and chemotherapy dose-finding trial of an allogeneic GM-CSF-secreting breast cancer vaccine given in a specifically timed sequence with immunomodulatory doses of cyclophosphamide and doxorubicin.
Emens LA, Armstrong D, Biedrzycki B, Davidson N, Davis-Sproul J, Fetting J, Jaffee E, Onners B, Piantadosi S, Reilly RT, Stearns V, Tartakovsky I, Visvanathan K, Wolff A. Emens LA, et al. Among authors: visvanathan k. Hum Gene Ther. 2004 Mar;15(3):313-37. doi: 10.1089/104303404322886165. Hum Gene Ther. 2004. PMID: 15018740 No abstract available.
American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction.
Visvanathan K, Chlebowski RT, Hurley P, Col NF, Ropka M, Collyar D, Morrow M, Runowicz C, Pritchard KI, Hagerty K, Arun B, Garber J, Vogel VG, Wade JL, Brown P, Cuzick J, Kramer BS, Lippman SM; American Society of Clinical Oncology. Visvanathan K, et al. J Clin Oncol. 2009 Jul 1;27(19):3235-58. doi: 10.1200/JCO.2008.20.5179. Epub 2009 May 26. J Clin Oncol. 2009. PMID: 19470930 Free PMC article.
The "luxury" of second malignancies.
Armstrong DK, Visvanathan K. Armstrong DK, et al. Among authors: visvanathan k. Gynecol Oncol. 2011 Dec;123(3):453-4. doi: 10.1016/j.ygyno.2011.09.016. Epub 2011 Oct 11. Gynecol Oncol. 2011. PMID: 21996261 No abstract available.
Declining second primary ovarian cancer after first primary breast cancer.
Schonfeld SJ, Berrington de Gonzalez A, Visvanathan K, Pfeiffer RM, Anderson WF. Schonfeld SJ, et al. Among authors: visvanathan k. J Clin Oncol. 2013 Feb 20;31(6):738-43. doi: 10.1200/JCO.2012.43.2757. Epub 2013 Jan 2. J Clin Oncol. 2013. PMID: 23284037 Free PMC article.
437 results